Use of Certolizumab Following Ileocolectomy Lowers Endoscopic and Histological Recurrence Rates for Crohn's Disease at One Year Compared to Mesalamine

Trial Profile

Use of Certolizumab Following Ileocolectomy Lowers Endoscopic and Histological Recurrence Rates for Crohn's Disease at One Year Compared to Mesalamine

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 12 Oct 2017

At a glance

  • Drugs Certolizumab pegol (Primary) ; Mesalazine
  • Indications Crohn's disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Jul 2016 Status changed from active, no longer recruiting to discontinued due to lack of accrual.
    • 15 Mar 2016 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.
    • 08 Apr 2015 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016,as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top